Quest Diagnostics unveiled a new artificial intelligence-based test service in the U.S. that aims to help physicians improve the detection of dementia and create better outcomes for patients. Through ...

Quest Diagnostics has seen its Fair Value Estimate rise moderately from $191.56 to $197.25 per share, reflecting a more optimistic outlook among analysts. This upward revision is largely due to strong ...

Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Though countless diagnostic developers struck it rich at the height of the COVID-19 pandemic, many of those that were relatively new to the testmaking game are now struggling to make up for lost sales ...

Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator ...

Quest Diagnostics, a nationwide medical testing company, will acquire some lab services from New York-Presbyterian in the coming months, the organizations announced Tuesday. The deal will allow ...

April 27 (Reuters) - Quest Diagnostics Inc (DGX.N), opens new tab posted first-quarter profit ahead of Wall Street estimates on Thursday as its base business helped offset a fall in COVID-19 test kits ...

Quest Diagnostics on Wednesday signaled an upbeat 2021 profit as COVID-19 testing volumes surged with the spread of the Omicron coronavirus variant in the United States. Quest said it performed over ...

Quest Diagnostics Inc. said Thursday its second-quarter net income fell to $234 million, or $1.96 a share from $631 million, or $4.96 a share in the year-ago quarter. Adjusted profit in the latest ...

Oct 21 (Reuters) - Quest Diagnostics Inc (DGX.N), opens new tab on Thursday warned that demand for COVID-19 molecular testing will slow down through the end of 2021 as infections decline, but a ...